Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office

Business Wire April 11, 2023

Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial

Business Wire April 5, 2023

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 3, 2023

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 6, 2023

Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates

Business Wire February 28, 2023

Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference

Business Wire February 24, 2023

Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023

Business Wire February 7, 2023

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 6, 2023

Aurinia Announces PTAB Has Terminated Inter Partes Review

Business Wire January 25, 2023

Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

Business Wire January 24, 2023

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results

Business Wire January 6, 2023

Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2023

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 3, 2023

Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals

Business Wire January 3, 2023

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 5, 2022

Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

Business Wire November 30, 2022

Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results

Business Wire November 3, 2022

Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022

Business Wire October 28, 2022

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022

Business Wire October 27, 2022

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 3, 2022